JP2019501216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501216A5 JP2019501216A5 JP2018547255A JP2018547255A JP2019501216A5 JP 2019501216 A5 JP2019501216 A5 JP 2019501216A5 JP 2018547255 A JP2018547255 A JP 2018547255A JP 2018547255 A JP2018547255 A JP 2018547255A JP 2019501216 A5 JP2019501216 A5 JP 2019501216A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- weight
- pharmaceutical composition
- dosage form
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002270 dispersing agent Substances 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 43
- 229920000642 polymer Polymers 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 11
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000007962 solid dispersion Substances 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 5
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 208000015658 resistant hypertension Diseases 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- CYSJNTQNMDWAJV-UHFFFAOYSA-N praliciguat Chemical compound C1=C(F)C(NCC(O)(C(F)(F)F)C(F)(F)F)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 CYSJNTQNMDWAJV-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 4
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021157646A JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260910P | 2015-11-30 | 2015-11-30 | |
| US62/260,910 | 2015-11-30 | ||
| US201662359440P | 2016-07-07 | 2016-07-07 | |
| US62/359,440 | 2016-07-07 | ||
| PCT/US2016/063312 WO2017095697A1 (en) | 2015-11-30 | 2016-11-22 | Solid dispersions comprising a sgc stimulator |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021157646A Division JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501216A JP2019501216A (ja) | 2019-01-17 |
| JP2019501216A5 true JP2019501216A5 (cg-RX-API-DMAC7.html) | 2020-01-09 |
| JP6952707B2 JP6952707B2 (ja) | 2021-10-20 |
Family
ID=57590822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547255A Active JP6952707B2 (ja) | 2015-11-30 | 2016-11-22 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
| JP2021157646A Active JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
| JP2023076655A Active JP7641320B2 (ja) | 2015-11-30 | 2023-05-08 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021157646A Active JP7277534B2 (ja) | 2015-11-30 | 2021-09-28 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
| JP2023076655A Active JP7641320B2 (ja) | 2015-11-30 | 2023-05-08 | ｓＧＣ刺激薬を含んでなる固体分散剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20190269619A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3383372B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6952707B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102841419B1 (cg-RX-API-DMAC7.html) |
| CN (4) | CN108883071A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016364976B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018011154B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3006746C (cg-RX-API-DMAC7.html) |
| EA (1) | EA201891315A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL259493B (cg-RX-API-DMAC7.html) |
| MX (3) | MX389961B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017095697A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017216429B2 (en) * | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| EA201990237A1 (ru) * | 2016-07-07 | 2019-08-30 | Сайклерион Терапьютикс, Инк. | Новые способы получения стимуляторов растворимой гуанилатциклазы |
| MX382762B (es) * | 2016-07-07 | 2025-03-13 | Cyclerion Therapeutics Inc | Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble. |
| WO2019055859A1 (en) | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| KR20250048609A (ko) | 2018-01-10 | 2025-04-09 | 사이클리온 테라퓨틱스, 인크. | 가용성 구아닐레이트 시클라제 자극제의 제조를 위한 신규 방법 및 중간체 |
| WO2019161534A1 (en) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators |
| WO2019172420A1 (ja) * | 2018-03-09 | 2019-09-12 | 協和発酵キリン株式会社 | 医薬組成物 |
| KR102755855B1 (ko) * | 2018-07-30 | 2025-01-15 | 가부시키가이샤 리코 | 입자의 제조 방법, 및 이 방법에 의해 제조된 입자 및 의약 |
| JP7503781B2 (ja) * | 2018-07-30 | 2024-06-21 | 株式会社リコー | 粒子の製造方法、並びに、それにより製造された粒子及び医薬 |
| US12409140B2 (en) * | 2019-09-23 | 2025-09-09 | Bionomics Limited | Therapeutic formulations and uses thereof |
| AU2020372900A1 (en) | 2019-10-29 | 2022-05-26 | Cyclerion Therapeutics, Inc. | Treatment of diabetic nephropathy with an sGC stimulator |
| KR20230121867A (ko) * | 2020-12-18 | 2023-08-21 | 유씨비 바이오파마 에스알엘 | 무정형 고체 분산체 |
| WO2023009710A1 (en) | 2021-07-28 | 2023-02-02 | Cyclerion Therapeutics, Inc. | Treatment of hfpef in post-menopausal women with an sgc stimulator |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0901786T3 (da) * | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| DE60039379D1 (de) * | 1999-02-10 | 2008-08-21 | Pfizer Prod Inc | Pharmazeutische feste Dispersionen |
| KR20140011366A (ko) * | 2011-03-08 | 2014-01-28 | 잘리커스 파마슈티컬즈 리미티드 | 고체 분산체 제형 및 그의 이용방법 |
| US9309235B2 (en) * | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| EA033168B1 (ru) * | 2013-03-15 | 2019-09-30 | Сайклерион Терапьютикс, Инк. | СТИМУЛЯТОРЫ sGC |
| WO2015106268A1 (en) * | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
-
2016
- 2016-11-22 AU AU2016364976A patent/AU2016364976B2/en active Active
- 2016-11-22 CA CA3006746A patent/CA3006746C/en active Active
- 2016-11-22 WO PCT/US2016/063312 patent/WO2017095697A1/en not_active Ceased
- 2016-11-22 CN CN201680077389.7A patent/CN108883071A/zh active Pending
- 2016-11-22 MX MX2018006422A patent/MX389961B/es unknown
- 2016-11-22 US US15/780,212 patent/US20190269619A1/en not_active Abandoned
- 2016-11-22 CN CN202310714714.8A patent/CN116942616A/zh active Pending
- 2016-11-22 JP JP2018547255A patent/JP6952707B2/ja active Active
- 2016-11-22 EP EP16816486.1A patent/EP3383372B1/en active Active
- 2016-11-22 CN CN202310714716.7A patent/CN116637076A/zh active Pending
- 2016-11-22 EA EA201891315A patent/EA201891315A1/ru unknown
- 2016-11-22 CN CN202310714725.6A patent/CN116637077A/zh active Pending
- 2016-11-22 KR KR1020187018204A patent/KR102841419B1/ko active Active
- 2016-11-22 BR BR112018011154-6A patent/BR112018011154B1/pt active IP Right Grant
-
2018
- 2018-05-21 IL IL259493A patent/IL259493B/en unknown
- 2018-05-24 MX MX2022001656A patent/MX2022001656A/es unknown
- 2018-05-24 MX MX2022001655A patent/MX2022001655A/es unknown
-
2021
- 2021-09-28 JP JP2021157646A patent/JP7277534B2/ja active Active
-
2022
- 2022-02-03 IL IL290338A patent/IL290338B2/en unknown
-
2023
- 2023-05-08 JP JP2023076655A patent/JP7641320B2/ja active Active
- 2023-12-29 US US18/400,392 patent/US20240293324A1/en not_active Abandoned
-
2024
- 2024-05-16 US US18/665,775 patent/US20250017862A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,072 patent/US20250255821A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501216A5 (cg-RX-API-DMAC7.html) | ||
| US20250332165A1 (en) | Pharmaceutical compositions of nilotinib | |
| CN103209686B (zh) | 固体组合物 | |
| JP6993502B2 (ja) | Ｓｇｌｔ－２阻害剤とアンジオテンシン受容体拮抗薬を含む医薬組成物 | |
| AU2012340759B2 (en) | Pharmaceutical formulations | |
| CN106232144B (zh) | 固体分散体 | |
| JP2005320354A5 (cg-RX-API-DMAC7.html) | ||
| JP2015534973A (ja) | 抗レトロウイルス医薬組成物 | |
| DK3034071T3 (en) | NEW COMBINATION | |
| CN102348455A (zh) | 药物剂型的活性包衣 | |
| JP2009215293A5 (cg-RX-API-DMAC7.html) | ||
| US20120264780A1 (en) | Solid compositions | |
| TW201444589A (zh) | 錠劑型式 | |
| JP6293315B2 (ja) | アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物 | |
| JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
| JP5854371B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤 | |
| AU691580B2 (en) | Antihyperglycaemic medicament | |
| CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| EP3925601B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| US20200054659A1 (en) | Extended release capecitabine capsules | |
| WO2024189127A1 (en) | Compositions for sustained release of poorly soluble active ingredients | |
| WO2025003956A1 (en) | High drug loading formulations of encorafenib | |
| GR1009209B (el) | Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου | |
| HK40006330A (en) | Solid compositions | |
| WO2018142359A1 (en) | Composition comprising immediate release and extended release capecitabine |